Author:
Liu Shufang,Li Zhe,Huisman Marc,Shah Dhaval K.
Funder
Center for Protein Therapeutics, University at Buffalo
National Institute of General Medical Sciences
National Institute of Allergy and Infectious Diseases
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Reference59 articles.
1. Covell DG, Barbet J, Holton OD, Black CD, Parker R, Weinstein JN (1986) Pharmacokinetics of monoclonal immunoglobulin G1, F (ab′) 2, and Fab′ in mice. Can Res 46(8):3969–3978
2. Baxter LT, Zhu H, Mackensen DG, Jain RK (1994) Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Can Res 54(6):1517–1528
3. Ferl GZ, Wu AM, DiStefano JJ (2005) A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 33(11):1640–1652
4. Garg A, Balthasar JP (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34(5):687–709. https://doi.org/10.1007/s10928-007-9065-1
5. Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39(1):67–86. https://doi.org/10.1007/s10928-011-9232-2